The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized, multi-center phase III trial of adjuvant chemotherapy with gemcitabine and capecitabine (GemCap) compared to capecitabine (Cap) alone in curatively resected biliary tract cancer (BilGemCap Study): KCSG HB20-14.
 
Joon Oh Park
Consulting or Advisory Role - AstraZeneca; Celgene; MediRama; Merck Serono; SERVIER
Research Funding - ABL Bio; Celgene; Eutilex; medpacto; SERVIER
 
Joon Seong Park
No Relationships to Disclose
 
Choong-kun Lee
Honoraria - Boryung; Dong-A ST; Novartis; SERVIER
Consulting or Advisory Role - AstraZeneca
 
Hong Jae Chon
No Relationships to Disclose
 
Sae Byeol Choi
No Relationships to Disclose
 
Dae Wook Hwang
No Relationships to Disclose
 
Do-Youn Oh
Consulting or Advisory Role - Arcus Biosciences; ASLAN Pharmaceuticals; AstraZeneca; Basilea; Bayer; BeiGene; Celgene; Genentech/Roche; Halozyme; IQVIA; Merck Serono; Novartis; Taiho Pharmaceutical; Turning Point Therapeutics; Yuhan; Zymeworks
Research Funding - Array BioPharma; AstraZeneca; BeiGene; Handok; Lilly; MSD; Novartis; SERVIER
 
Myung Ah Lee
Consulting or Advisory Role - ElmediX; Green Cross; Roche; SERVIER; Yuhan
Speakers' Bureau - Yuhan
 
Jin-Young Jang
No Relationships to Disclose
 
Baek-Yeol Ryoo
No Relationships to Disclose